SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 CY2025, ...